We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Diabetes & Endocrinology

Empagliflozin Protects the Kidney Across Clinical Spectra — Acute Dip Is Not a Dealbreaker

MedXY Editorial Team•Nov 28, 2025•Diabetes & Endocrinology
chronic kidney diseaseempagliflozinSGLT2 inhibitors

Highlight

• In an individual participant-level meta-analysis of 23,340 participants from four large randomized trials (EMPA-REG OUTCOME, EMPEROR-Reduced, EMPEROR-Preserved, EMPA-KIDNEY), empagliflozin reduced acute kidney injury markers and adverse events, slowed chronic eGFR decline, and lowered progression to kidney failure.

• These kidney benefits were consistent across subgroups defined by predicted size of the early eGFR dip, diabetes status, heart failure status, baseline kidney function, albuminuria level, and primary kidney disease.

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Empagliflozin Demonstrates Uniform Cardiovascular Benefits Across Diverse Patient Subgroups in Type 2 Diabetes: Insights from the EMPRISE Real-World StudyEmpagliflozin consistently reduces major cardiovascular events, heart failure hospitalizations, and mortality across diverse sociodemographic and cardiovascular risk groups in older adults with type 2 diabetes, with especially pronounced abSep 23, 2026Longitudinal Glycemic Trajectories in Adults with Type 1 Diabetes: Insights from a Three-Year Multicenter CGM StudyThis study investigates three-year continuous glucose monitoring trajectories across clinical subgroups of adults with type 1 diabetes to identify factors influencing glycemic control and variability, highlighting the need for individualizeSep 21, 2026Efficacy and Safety of Low-Dose Rivaroxaban in Advanced Chronic Kidney Disease with High Cardiovascular Risk: A Comprehensive ReviewLow-dose rivaroxaban failed to reduce cardiovascular events but increased major bleeding in advanced CKD patients at high cardiovascular risk, underscoring the need for cautious anticoagulant use.Sep 21, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
General Surgery
Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
KDIGO 2026 on Anemia in CKD: Key Recommendations and Practical Guidance for Clinicians
KDIGO 2026 updates anemia care in CKD: evidence-based thresholds for iron therapy, preference for IV iron on hemodialysis, ESA-first approach over HIF-PHIs, individualized Hb initiation, and an ESA maintenance upper Hb target <11.5 g/dL.
Sep 18, 2026
SGLT2 Inhibitors Enhance Recovery After Endovascular Thrombectomy in Diabetic Stroke Patients: A Multicenter Retrospective StudySGLT2 inhibitors administered after endovascular thrombectomy in diabetic stroke patients significantly improve 3-month functional outcomes, suggesting a promising adjunctive therapy for poststroke diabetes management.Sep 18, 2026
Ketoacidosis Risk with SGLT2 Inhibitors in Type 2 Diabetes: Insights from a Scandinavian Cohort StudyA large Scandinavian study reveals that ketoacidosis risk during SGLT2 inhibitor therapy in type 2 diabetes varies by patient factors and persists beyond early treatment, highlighting the need for ongoing risk assessment and management straSep 5, 2026